Exclusive process for extracting and microencapsulating cannabinoids allows AXIM® to create pharmaceutical grade cannabinoid ingredients.
AXIM® Biotechnologies leads the industry in cannabinoid research and treatment innovation with 20 separate cannabis-based pharmaceuticals currently in development.
Giving AXIM® a further edge, the company recently announced that it has successfully executed its proprietary current good manufacturing practices (“cGMP”) methods for extraction and microencapsulation of cannabinoid molecules. These high purity, microencapsulated cannabinoids are ideal for development into a variety of pharmaceutical applications.
This breakthrough achievement makes AXIM® Biotechnologies the only company in the world to apply this proprietary procedure to providing pure Active Pharmaceutical Ingredients (“APIs”) from naturally sourced cannabinoids.
Proprietary Method for Cannabinoid Extraction and Purification
AXIM® Biotechnologies’ unprecedented manufacturing methods begin with carefully cultivated cannabis plants grown in an approved facility. After the plants are harvested, the company extracts the plants oil, including its valuable cannabinoids. In an innovative two-step process that achieves an average cannabinoid purity of more than 99 percent, AXIM® is able to create the highest quality cannabinoids for use as active pharmaceutical ingredients.
The process, which was developed in the Netherlands under strict regulatory guidelines, follows strict cGMP standards from cultivation through manufacturing to ensure consistently high purity results.
AXIM® Biotechnologies doesn’t use toxic solvents like some traditional cannabinoid extraction processes. Nor are its resulting cannabinoids synthesized like the API dronabinol. Instead, AXIM® creates its cannabinoid APIs from all-natural cannabis plants.
Pharmaceutical Grade Encapsulated Cannabinoids
After the extraction and purification of the cannabinoids, AXIM® applies its newly developed microencapsulation method is applied to the cannabinoids.
Microencapsulation surrounds an active material core with an outer shell or membrane. This microencapsulation protects the cannabinoid core from deterioration from oxidation, etc., while preserving effectiveness. Microencapsulation can also be used to control the release of active ingredients and can potentially increase bioavailability of APIs.
“We’re thrilled to be able to announce this new method to the industry,” said George E. Anastassov, MD, DDS, MBA, and Chief Executive Officer of AXIM Biotech. “Our innovative extraction process achieves reliable and effective results while providing a high purity level. By microencapsulating these molecules, we are able to protect them and preserve the APIs while increasing their bioavailability and the potential therapeutic benefits for a variety of pharmaceutical applications.”
AXIM® Biotechnologies then formulates its microencapsulated cannabinoids into a number of pharmaceutical products. Due to the microencapsulated cannabinoids’ versatility in use, it is manufactured into transdermal delivery systems, suppositories, capsules, ocular applications, and its patented cannabinoid chewing gum.
AXIM® Looks to Create Novel Cannabinoid-Based Treatments
Using these delivery systems, AXIM® Biotechnologies is developing a number of cannabinoid-based pharmaceutical treatments, many for hard to treat medical indications. AXIM® currently owns two patents and is awaiting confirmation of an additional 12 patent applications.
To date, AXIM® has formulated over 20 diversified products, targeting conditions that include
- Irritable Bowel Syndrome
- Psoriasis/Atopic Dermatitis
- Multiple Sclerosis: Pain & Spasticity
- Nausea/Vomiting/Loss of Appetite
- Crohn’s Disease
- Inflammatory Bowel Disease
- Opioid Addiction
- Restless Leg Syndrome
- Drug-Related Psychosis
- Dry Eye
- Post-herpetic Neuralgia
- Parkinson’s Disease
- Tobacco Smoking Cessation
“At AXIM, we’re committed to best practices and innovation, and the fact that we can apply this new and fully cGMP compliant process to a number of applications is very exciting,” said Anastassov. “We’re confident that our work in developing both these cGMP methods, along with our diversified delivery systems and products, will expand the pharmaceutical cannabinoid market and broaden the potential areas of application based on specific indications.”
These new treatments include AXIM’s proprietary chewing gum products CanChew+® and MedChew Rx® which have been developed to treat IBS symptoms and the treatment of pain and spasticity associated with MS, respectively.
Learn More About AXIM® Biotechnologies